Reaction
Cervix Carcinoma Recurrent reporting signals
As of the last recalculation, Cervix Carcinoma Recurrent appears in 168 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is PACLITAXEL (AIBUMIN-BOUND) (PRR 92.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Paclitaxel (Aibumin-Bound) | 45 | 92.3 | 92.3 |
| Carboplatin | 55 | 79.3 | 79.3 |
| Paclitaxel | 45 | 76.5 | 76.6 |
| Pembrolizumab | 35 | 51.8 | 51.8 |
| Axitinib | 6 | 39.5 | 39.6 |